FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.69% for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2020-11-16
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-09-30 was 0.69%, a 57.67% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-09-30 was 1.63%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.70%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-09-30 was 2.04%, a 60.63% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2020-09-30 | 0.69% 10-Q · filed 2020-11-16 | ||||
| 2019-09-30 | 1.63% 10-Q · filed 2020-11-16 | ||||
| 2019-02-01 | 2.70% 10-Q · filed 2019-11-12 | 2.70% 10-Q · filed 2020-11-16 | |||
| 2018-03-31 | 2.70% 10-Q · filed 2018-05-14 | ||||
| 2017-09-30 | 2.04% 10-Q · filed 2018-11-13 | ||||
| 2016-09-30 | 1.27% 10-Q · filed 2017-11-13 | ||||
| 2016-06-30 | 1.51% 10-Q · filed 2017-08-14 | ||||
| 2015-09-30 | 1.89% 10-Q · filed 2016-11-14 | ||||
| 2015-06-30 | 2.00% 10-Q · filed 2016-08-12 | ||||
| 2015-03-31 | 1.90% 10-Q · filed 2016-05-12 | ||||
| 2014-12-31 | 0.67% 10-Q · filed 2016-05-12 | ||||
| 2012-09-30 | 1.26% 10-Q · filed 2013-11-18 | ||||
| 2011-09-30 | 2.50% 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |